Exciting developments have unfolded this week, with the confirmation that the Therapeutic Goods Administration (TGA) have given approval for the expanded use of Trikafta to encompass children aged 2 to 5 years with CF who carry at least one F508del mutation in the CFTR gene.
The forthcoming Pharmaceutical Benefits Advisory Committee (PBAC) meeting in March will determine whether this expansion will be included on the Pharmaceutical Benefits Scheme (PBS).
We anticipate news of this outcome on 26 April and and will keep you informed every step of the way.